drugset
Drugs / eganelisib
last change Jul 2026 re-read 2 minutes ago

eganelisib

also known as IPI-549 · Pi3k-gamma inhibitor ipi-549

Small molecule targets PIK3CG via inhibition

Developed for
acute myeloid leukemia · head and neck squamous cell carcinoma · triple-negative breast carcinoma · adrenal cortex carcinoma · breast cancer · human papillomavirus-related squamous cell carcinoma · melanoma · mesothelioma
+6 more · myelodysplastic syndrome · non-small cell lung carcinoma · ovarian cancer · renal cell carcinoma · urinary bladder cancer · urothelial carcinoma
Investigated by
Infinity Pharmaceuticals, Inc. · Stelexis BioSciences · Arcus Biosciences, Inc. · Assuntina G. Sacco, MD · Bristol-Myers Squibb · Jacqueline Garcia, MD
+2 more · Roche Pharma AG · The V Foundation for Cancer Research

Trials 7 · a red edge is where a trial was stopped

today NCT07439211 · Ph 1 NCT06533761 · Ph 1 NCT03795610 · Ph 2 NCT03961698 · Ph 2 NCT03980041 · Ph 2 NCT03719326 · Ph 1 NCT02637531 · Ph 1
2016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT07439211 Jul 2026 → Feb 2028 expected acute myeloid leukemia Jacqueline Garcia, MD Not yet recruiting No outcome recorded
Phase 1 NCT06533761 Apr 2025 → Jul 2027 expected acute myeloid leukemia, myelodysplastic syndrome Stelexis BioSciences Recruiting No outcome recorded
Phase 1 NCT03719326 Oct 2018 → Jul 2021 ovarian cancer, triple-negative breast carcinoma Arcus Biosciences, Inc. Completed No outcome recorded
Phase 1 NCT02637531 Dec 2015 → Jan 2022 adrenal cortex carcinoma, head and neck squamous cell carcinoma, melanoma, mesothelioma +2 Infinity Pharmaceuticals, Inc. Unknown No outcome recorded
Phase 23 trials
Phase 2 NCT03795610 Mar 2020 → Dec 2022 head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma Assuntina G. Sacco, MD Completed No outcome recorded
Phase 2 NCT03961698 Dec 2019 → Aug 2023 breast cancer, renal cell carcinoma Infinity Pharmaceuticals, Inc. Unknown No outcome recorded
Phase 2 NCT03980041 Sep 2019 → Nov 2020 urinary bladder cancer, urothelial carcinoma Infinity Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as eganelisib “Drug: IPI-549 (eganelisib)” NCT03980041 ↗
4

“Drug: IPI-549 (eganelisib)” NCT02637531 ↗

“IPI-549 (eganelisib)” NCT03961698 ↗

NCT06533761 ↗

NCT07439211 ↗
Known as IPI-549 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02637531 ↗
4

NCT03961698 ↗

NCT03719326 ↗

NCT03980041 ↗

NCT03795610 ↗
Known as Pi3k-gamma inhibitor ipi-549 ChEMBL registry synonym — accepted as the source's own label CHEMBL3984425 ↗
Action Inhibit “IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use” NCT03719326 ↗
1

“PI3-kinase p110-gamma subunit inhibitor” CHEMBL3984425 ↗
Modality Small molecule — CHEMBL3984425 ↗
Route Oral “IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)” NCT02637531 ↗
Target PIK3CG “PI3-kinase p110-gamma subunit inhibitor” CHEMBL3984425 ↗